Cognitive screening performance in patients with inflammatory bowel disease in remission: a case-control study
Crohn’s & Colitis 360 · 05.10.2026 · 8 (4)
DOI: 10.1093/crocol/otag108 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 29.10.2026. Verfasst von Costantino Sgamato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Gastroenterology, University Federico II, Naples, Italy. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Background
Emerging evidence links inflammatory bowel disease (IBD) to neurological and mood disorders, but cognitive function in this population remains understudied. By using Montreal Cognitive Assessment (MoCA) we screened for mild cognitive impairment (MCI) patients with IBD and healthy controls (HC).
Methods
We enrolled a highly selected cohort of 120 patients with IBD in clinical, biochemical, and endoscopic remission (59 with ulcerative colitis [UC] and 61 with Crohn’s disease [CD]) and 115 matched HC. A MoCA score <26 was considered a below-threshold cognitive screening result, not a clinical diagnosis of mild cognitive impairment. The Hospital Anxiety and Depression Scale (HADS) was used to assess current symptoms rather than establish psychiatric diagnoses.
Results
MoCA scores <26 were more frequent among patients with IBD than HC (57% vs. 42%, P = .016), even after excluding participants with HADS scores in the probable-symptom range (57.9% vs. 37.5%, P = .009). Mean total MoCA scores did not differ significantly between groups (25.0 vs. 25.3, P = .280). In exploratory subgroup comparisons, patients with UC had lower naming-domain scores than HC (P = .002). In multivariable analysis, age (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.0–1.1; P = .002), IBD diagnosis (OR 3.07, 95% CI 1.4–6.4; P = .003), and years of schooling (OR 0.85, 95% CI 0.7–1.0; P = .030) were independently associated with a MoCA score <26. After excluding participants with HADS scores in the probable-symptom range, IBD diagnosis (OR 2.72, 95% CI 1.1–6.5; P = .025) and years of schooling (OR 0.71, 95% CI 0.6–0.9; P = .001) remained associated with a below-threshold score.
Conclusions
In this highly selected sample, IBD was associated with a greater proportion of below-threshold MoCA scores. These findings reflect cognitive performance and do not establish a higher prevalence of cognitive impairment, a causal mechanism, or a rationale for universal screening. Longitudinal studies incorporating diagnostic neuropsychological assessment are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Gastroenterology, University Federico II, Naples, Italy.
ORCID-Profile: Costantino Sgamato, Carmen Ambrosio, Stefano Minieri, Alba Rocco, Gerardo Nardone, Debora Compare
Förderung
- Johnson & Johnson
Zitieren
APA
Sgamato, C., Ambrosio, C., Minieri, S., Zerella, G., Rocco, A., Coccoli, P., Nardone, G., & Compare, D. (2026). Cognitive screening performance in patients with inflammatory bowel disease in remission: a case-control study. Crohn’s & Colitis 360, 8(4). https://doi.org/10.1093/crocol/otag108
Vancouver
Sgamato C, Ambrosio C, Minieri S, Zerella G, Rocco A, Coccoli P, et al. Cognitive screening performance in patients with inflammatory bowel disease in remission: a case-control study. Crohn’s & Colitis 360. 2026;8(4). doi:10.1093/crocol/otag108
BibTeX
@article{Sgamato2026,
author = {Sgamato, Costantino and Ambrosio, Carmen and Minieri, Stefano and Zerella, Giovanni and Rocco, Alba and Coccoli, Pietro and Nardone, Gerardo and Compare, Debora},
title = {Cognitive screening performance in patients with inflammatory bowel disease in remission: a case-control study},
journal = {Crohn’s & Colitis 360},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/crocol/otag108}
}
EUVIMED